<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696748</url>
  </required_header>
  <id_info>
    <org_study_id>U00006KO</org_study_id>
    <nct_id>NCT00696748</nct_id>
  </id_info>
  <brief_title>The Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men</brief_title>
  <acronym>NePlaM3</acronym>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study With Open-Label Follow-up to Investigate the Effect of IM Testosterone Undecanoate on Biochemical and Anthropometric Characteristics of Metabolic Syndrome in Hypogonadal Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Russian Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Russian Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the effect of the testosterone therapy on the body
      composition, lipid and glucose metabolism, inflammatory markers in patients with metabolic
      syndrome and hypogonadism.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2005</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>waist-to-hip ratio</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Men receiving Nebido</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Men receiving Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebido (testosterone undecanoate)</intervention_name>
    <description>Nebido (testosterone undecanoate) intramuscular 4 ml by scheme</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 4 mL intramuscular</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed informed consent to participate in the study

          -  Men aged 35 to 70 with testosterone levels below 12 nmol/L or free testosterone below
             225 pmol/L

          -  Presence of the metabolic syndrome according to the IDF definition

        Exclusion Criteria:

          -  Patients under 35 or above 70 years.

          -  Participation in any clinical study within 30 days before the first injection of the
             drug

          -  Simultaneous participation in another clinical study

          -  Incapable subjects as well as prisoners

          -  Suspicion of a serious organic or mental disease according to medical history and/or
             clinical examination

          -  Prostate cancer, breast cancer or suspicion thereof

          -  Presence or history of hepatic tumors

          -  Acute or chronic hepatic disease

          -  Presence of renal diseases with renal failure

          -  Changes in biochemical or hematological laboratory values in spite of lack of clinical
             manifestations, in the investigator's opinion

          -  Suspected lack of the patient's compliance

          -  Hypersensitivity to the active substance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetlana Kalinchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Center for Endocrinology, Russia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Svetlana Kalinchenko, PhD</last_name>
    <phone>+70951244301</phone>
    <email>kalinchenko@list.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuliya Tishova</last_name>
    <phone>+79032213276</phone>
    <email>yulya_tishova@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scientific Centre for Endocrinology RAMS</name>
      <address>
        <city>Moscow</city>
        <zip>117136</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Svetlana Kalinchenko, PhD</last_name>
      <phone>+7(095)1244301</phone>
      <email>kalinchenko@list.ru</email>
    </contact>
    <contact_backup>
      <last_name>Yuliya Tishova, PhDstudent</last_name>
      <phone>+79032213276</phone>
      <email>yulya_tishova@mail.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Tishova Yulya, PhD student</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <last_update_submitted>June 11, 2008</last_update_submitted>
  <last_update_submitted_qc>June 11, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Svetlana Kalinchenko</name_title>
    <organization>Russian Research Center for Endocrinology</organization>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>hypogonadism</keyword>
  <keyword>testosterone undecanoate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

